Find disease awareness content and relevant supporting materials
Superiority of Orsiro DES over Xience DES confirmed in STEMI patients according to new follow-up data from the BIOSTEMI trial.- Biotronik.
Biotronik’s ultrathin-strut stent, Orsiro, demonstrated superiority over Xience DES for target lesion failure (TLF) at 24 months, according to new follow-up data from the BIOSTEMI trial.
PLATINUM study of the Promus Premier Everolimus-Eluting Platinum Chromium Coronary Stent finds little difference in outcomes between patients groups in coronary artery disease- Boston Scientific
Boston Scientific has reported results of the PLATINUM Diversity study to evaluate the clinical outcomes of the Promus Premier Everolimus-Eluting...